Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:32:33.950Z.
Calculation as of: 2026-10-06T15:32:33.950Z.
Quote observation: 2026-10-06T15:30:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f3696a2d024229c19dd1691f2f438020e28c75ff27c8cf4c9d796e14bd4a3b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$25.22M
EV/EBIT Ratio
N/A
TTM Avg
11456.84x
3Y Avg
11456.84x
5Y Avg
11456.84x
Market Cap
$24.09M
EV/EBIT Ratio
N/A
TTM Avg
104.01x
3Y Avg
104.01x
5Y Avg
104.01x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $25.43M | N/A | N/A | N/A | N/A |
| InspireMD, Inc. (NSPR)vs › | $26.75M | N/A | N/A | N/A | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.55M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.22M | N/A | 11456.84x | 11456.84x | 11456.84x |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.51M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.49M | N/A | N/A | N/A | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $24.09M | N/A | 104.01x | 104.01x | 104.01x |
| OneMedNet Corporation (ONMD)vs › | $29.77M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.18M | N/A | 0.37x | 0.82x | 0.82x |
| GridAI Technologies Corp. (GRDX)vs › | $30.31M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
